Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.ERNA · Entity 8278 | Sr. VP of Finance | June 21, 2025 | July 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date June 21, 2025 · Filed July 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110 |
Reported balance
After 2025-06-21 transaction · row 1
1 source rowRow 1 · 2025-06-21 · Exercise / conversion · Acquired 30 · Balance 110 F1: Each restricted stock unit converts into one share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-21 · Exercise / conversion · Acquired 30 · Balance 0 F1: Each restricted stock unit converts into one share of common stock. F2: On June 21, 2021, the reporting person was granted 118 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit converts into one share of common stock.
F2: On June 21, 2021, the reporting person was granted 118 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2018 Filed Mar 21, 2018 20:55 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-003716 · form4.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,304 F1 · shares: Represents shares subject to a restricted stock unit award granted under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan. The award will vest as to 16.67% of the shares subject to the award on the 6-month anniversary of the grant date and the remaining 83.33% of the shares will vest in 30 substantially equal monthly installments beginning on the 7-month anniversary of the grant date, in each case, subject to the reporting person's continued service to the issuer as of the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.